MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-19-2026
Aeglea BioTherapeutics Total Current Liabilities 2011-2026 | AGLE
Annual Total Current Liabilities Aeglea BioTherapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 58.7 M | 54.1 M | 32 M | 14.7 M | 20.1 M | 16.4 M | 18.4 M | 10.2 M | 5.63 M | 3.96 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 58.7 M | 3.96 M | 23.4 M |
Total Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
I-Mab
IMAB
|
576 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.62 B | - | - | $ 40.3 B |  USA |
 |
Apellis Pharmaceuticals
APLS
|
324 M | $ 20.29 | -1.98 % | $ 2.56 B | USA |
 |
Aptorum Group Limited
APM
|
4.34 M | $ 0.8 | -5.3 % | $ 4.36 M | China |
 |
Axsome Therapeutics
AXSM
|
379 M | $ 166.0 | -0.23 % | $ 8.26 B | USA |
 |
AbCellera Biologics
ABCL
|
64.3 M | $ 3.74 | -2.23 % | $ 1.12 B |  Canada |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.77 M | - | -1.52 % | $ 24.7 M | USA |
 |
Certara
CERT
|
153 M | $ 7.22 | 2.34 % | $ 1.16 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
147 M | $ 23.78 | -0.42 % | $ 2.91 B | USA |
 |
Corvus Pharmaceuticals
CRVS
|
6.87 M | $ 18.17 | 1.57 % | $ 873 M | USA |
 |
Adverum Biotechnologies
ADVM
|
22.9 M | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
556 M | - | - | - |  Russia |
 |
ARCA biopharma
ABIO
|
13 M | - | 1052.0 % | $ 415 M | USA |
 |
Eton Pharmaceuticals
ETON
|
16.2 M | $ 17.9 | -1.38 % | $ 459 M | USA |
 |
Exelixis
EXEL
|
406 M | $ 40.5 | -1.29 % | $ 11 B | USA |
 |
Acer Therapeutics
ACER
|
19 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
58 M | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
228 M | - | -24.86 % | $ 820 K | USA |
 |
Galectin Therapeutics
GALT
|
35.4 M | $ 2.89 | -5.56 % | $ 180 M | USA |
 |
Capricor Therapeutics
CAPR
|
31.3 M | $ 26.3 | -2.08 % | $ 704 M | USA |
 |
Acasti Pharma
ACST
|
1.93 M | - | 4.01 % | $ 150 M | Canada |
 |
Codexis
CDXS
|
23.6 M | $ 1.02 | -0.33 % | $ 74.9 M | USA |
 |
Greenwich LifeSciences
GLSI
|
1.56 M | $ 27.88 | 1.79 % | $ 363 M | USA |
 |
Galecto
GLTO
|
5.83 M | $ 29.63 | -1.41 % | $ 787 M |  Danmark |
 |
Halozyme Therapeutics
HALO
|
177 M | $ 68.58 | -1.82 % | $ 8.22 B | USA |
 |
Hoth Therapeutics
HOTH
|
831 K | $ 1.0 | -1.47 % | $ 6.38 M | USA |
 |
AgeX Therapeutics
AGE
|
5.91 M | - | -10.17 % | $ 12.2 K | USA |
 |
Harmony Biosciences Holdings
HRMY
|
252 M | $ 28.32 | -2.01 % | $ 1.63 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
25.2 M | - | - | $ 26.5 M | USA |
 |
ImmuCell Corporation
ICCC
|
4.41 M | $ 6.3 | -3.67 % | $ 51.5 M | USA |
 |
AIkido Pharma
AIKI
|
3.78 M | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
256 M | $ 3.27 | -2.1 % | $ 1.17 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.54 M | - | - | $ 7.46 M |  Israel |
 |
Akero Therapeutics
AKRO
|
39.8 M | - | - | $ 3.67 B | USA |
 |
Agios Pharmaceuticals
AGIO
|
82.2 M | $ 28.57 | -2.16 % | $ 1.66 B | USA |
 |
Immunic
IMUX
|
30.6 M | $ 1.13 | 6.61 % | $ 176 M | USA |
 |
Immunovant
IMVT
|
68.8 M | $ 27.09 | -2.38 % | $ 4.11 B | USA |
 |
Inhibrx
INBX
|
56.3 M | $ 76.39 | -1.42 % | $ 3.6 B | USA |
 |
InMed Pharmaceuticals
INM
|
2 M | $ 0.8 | -2.44 % | $ 1.96 M | Canada |